Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca (AZN) Q4 Earnings, Sales Top Despite COVID-19 Woes

AstraZeneca (AZN) surpasses fourth-quarter estimates on both counts. Stock up in pre-market.

Deciphera (DCPH) Reports Narrower-Than-Expected Q4 Loss

Deciphera Pharmaceuticals (DCPH) reports narrower-than-expected loss. Nonetheless, sales marginally surpass estimates for the fourth quarter of 2020.

Bristol Myers (BMY) Gets European Commission Nod for Inrebic

The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.

Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug

Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.

Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV

The approval of Glaxo's (GSK) Rukobia is based on data from the pivotal phase III BRIGHTE study. Rukobia was approved in the United States in July last year.

Corcept (CORT) Posts Preliminary '20 Results, Gives 2021 View

Corcept (CORT) provides preliminary revenue figures for fourth-quarter and full-year 2020. The company also issues revenue guidance for 2021. Shares down in after-hours trading.

Cassava (SAVA) Rises on Late-Stage Alzheimer's Study Plans

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips

The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips

Sweta Killa headshot

Pharma ETFs in Focus Post Q4 Earnings

Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.

Sheraz Mian headshot

Top Stock Reports for Alphabet, Pfizer & Uber

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Pfizer (PFE), and Uber Technologies (UBER).

J&J (JNJ) Seeks Emergency Approval for Coronavirus Vaccine

Johnson & Johnson (JNJ) submits regulatory application to the FDA seeking emergency use approval for its single-shot coronavirus vaccine.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK Q4 Earnings, AZN, JNJ Coronavirus Vaccine Updates

Several companies announce Q4 results. J&J (JNJ) and AstraZeneca (AZN) provide updates on their respective COVID-19 vaccines.

Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised

Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.

Glaxo (GSK) Q4 Earnings Lag Estimates, Shingrix Back on Track

Glaxo's (GSK) Shingrix shows strong recovery during the quarter. However, negative impact of COVID-19 hurts sales of Pharmaceuticals and Consumer Healthcare segment.

Cassava (SAVA) Soars on Encouraging Alzheimer's Study Data

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

Markets Return to Normalcy

Markets Return to Normalcy

Mark Vickery headshot

Groundhog Day, But Nothing's the Same: Q4 for PFE, UPS

We can also take a look at GameStop (GME), AMC Entertainment (AMC) and the silver commodity and recognize that it's not "deja vu all over again" (to quote Yogi Berra); it is a return to valuation normalcy.

Pfizer (PFE) Q4 Earnings Miss, Sales Beat, 2021 View Upbeat

Pfizer (PFE) misses estimates for earnings while beating the same for sales. It provides an upbeat financial outlook for 2021.

Pfizer (PFE) Misses Q4 Earnings Estimates

Pfizer (PFE) delivered earnings and revenue surprises of -8.70% and 6.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Markets Await Economic and Earnings Data

Markets Await Economic and Earnings Data

J&J's (JNJ) Coronavirus Vaccine Shows 66% Efficacy in Phase III

J&J's (JNJ) phase III ENSEMBLE study on its single-dose COVID-19 vaccine candidate meets all primary and key secondary endpoints.

Drug/Biotech Stock Earnings on Feb 2: AMGN, PFE & CTLT

Let us take a look at three drug/biotech companies, AMGN, PFE, CTLT, which are gearing up for their earnings release.

John Blank headshot

Did r/WallStreetBets Smother the Bull Market?

Institutional traders are taking profits off the table, respecting very rich, fully priced in, stock market valuations. However, there is a lot of risk de-leveraging and capital building going on, too.

Mark Vickery headshot

Another Big Week for Q4 Earnings, Econ News; ON Semi Beats

Q4 earnings season keeps going full-throttle this week, with lots of household names reporting quarterly earnings.

Pfizer, United Parcel Service, Amazon, Google and Boeing are part of Zacks Earnings Preview

Pfizer, United Parcel Service, Amazon, Google and Boeing are part of Zacks Earnings Preview